Furthermore, in breast cancer, one phase 2 study in the triple-negative subtype showed that DA was effective [22], while another phase 2 study showed that DA monotherapy was more effective in patients with hormone-receptor-positive breast cancer in comparison with HER2-positive breast cancer [23]. This evidence concerns the gene NR4A1 and breast carcinoma.